文献速递血栓与止血

成人难治性免疫性血小板减少症:迈向新定义

Refractory immune thrombocytopenia in adults: Towards a new definition.
PubMed 文献 · Br J Haematol · 2023-08-29

免疫性血小板减少症(ITP)患者经多线治疗后仍无血小板反应者被称为难治性,但该词含义已模糊。作者回顾既往定义、调查20名ITP专家并收集登记处数据,95%专家认为需新定义,85%支持注明失败治疗类型与时机,据此提出可供未来研究评估的难治性ITP定义。

要点

  • 95%的ITP专家认为临床与研究均需新的难治性ITP定义。
  • 85%受访专家支持使用「难治性」一词并注明失败治疗的类型与时机。
  • McMaster与挪威ITP登记处初步数据显示成人ITP患者失败一线治疗、利妥昔单抗、血小板生成素受体激动剂、任何免疫抑制剂及脾切除的比例为0.4%至3.8%。

核心结论

  • 作者提出一个可在未来研究中评估的难治性ITP定义,该定义使用「难治性」一词并明确标注失败治疗的类型与时机。

研究设计与样本

  • 作者回顾既往难治性ITP定义,征询ITP专家意见并收集登记处数据以形成定义。
  • 2022年9月参加洲际协作ITP研究组第7次专家会议的20名ITP专家回答了网络调查。
  • 初步数据来自McMaster与挪威ITP登记处。

主要发现

  • 95%的受访专家认为临床与研究目的均需要新的难治性ITP定义。
  • 85%的受访者支持使用「难治性」一词并明确标注失败治疗的类型与时机。
  • 登记处初步数据显示,成人ITP患者失败一线治疗、利妥昔单抗、血小板生成素受体激动剂、任何免疫抑制剂及脾切除的比例范围为0.4%至3.8%。

关键数值与推荐

  • 专家调查中95%认为需要新的难治性ITP定义。
  • 专家调查中85%支持使用「难治性」一词并注明失败治疗的类型与时机。
  • 登记处初步数据中成人ITP患者失败一线治疗、利妥昔单抗、血小板生成素受体激动剂、任何免疫抑制剂及脾切除的比例为0.4%至3.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune thrombocytopenia (ITP) is an autoimmune haematological disorder characterized by immune-mediated thrombocytopenia and a variable risk of bleeding. Despite the availability of multiple treatment options, some patients are considered refractory since they do not achieve a platelet count response to multiple treatments and are at risk of bleeding. The term 'refractory' has been used to identify this patient group; however, with the advent of multiple lines of treatment, its meaning has become ambiguous. To address this issue, we reviewed previous definitions of refractory ITP, solicited the views of ITP experts and collected data from registries to inform a definition. Twenty ITP experts who attended the 7th Expert Meeting of the Intercontinental Cooperative ITP Study Group in September 2022 answered a web-based survey: 95% felt that there was a need for a new definition of refractory ITP for clinical and research purposes. The use of the term refractory, accompanied by a clear indication of the type and timing of failed treatments, was supported by 85% of respondents. Preliminary data on the frequency of refractory patients from the McMaster and Norwegian ITP Registries demonstrated that the proportion of adult ITP patients who had failed first-line therapy, rituximab, thrombopoietin receptor agonists, any immune suppressant medication and splenectomy ranged from 0.4% to 3.8%. We propose a definition of refractory ITP that could be evaluated in future studies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Arnold DM, Clerici B, Ilicheva E, et al. Refractory immune thrombocytopenia in adults: Towards a new definition. Br J Haematol. 2023. PMID: 37642211. doi:10.1111/bjh.19075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。